Zacks Investment Research
21 Jul 2026, 15:50 UTC · 4h ago
Acadia Gets FDA's Fast Track Tag for Alzheimer's Disease Candidate
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
21 Jul 2026, 15:50 UTC · 4h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
The FDA granted Fast Track designation to Acadia Pharmaceuticals' drug remlifanserin for the treatment of Alzheimer’s disease psychosis (ADP). — Fast Track status accelerates the development and review process for a drug targeting a condition with no currently FDA-approved therapies.
+0.60Acadia expects to report top-line results from the phase II portion of the RADIANT program for remlifanserin between September and October 2026. — Top-line data results are primary binary catalysts for biotech stocks that determine whether a drug proceeds to final approval.
+0.40Acadia projects combined net sales of approximately $1.7 billion by 2028 from its lead products, Nuplazid and Daybue. — Provides a concrete long-term revenue target that helps analysts value the company's current commercial success.
+0.30Continue reading
6 related stories
Top 1 mover · tap to explore
Acadia is expanding its clinical pipeline with studies for Lewy Body Dementia with Psychosis, essential tremor, and major depressive disorder. — Diversifying the pipeline reduces reliance on a single drug candidate, though these are early-to-mid stage developments.
+0.20Which stocks this story touches
The FDA granted Fast Track designation to its investigational drug remlifanserin for Alzheimer's disease psychosis.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
3h ago
